What you should know:
1. Naia is developing a short bowel syndrome treatment and has other GI drugs in the pipeline.
2. RDD Pharma expects to close the deal after its merger with Innovate Biopharmaceuticals closes, forming 9 Meters Biopharma.
3. Naia will receive a combination of cash and shares in 9 Meters Biopharma if both deals close.
More articles on surgery centers:
CMS to pay for total knees in ASCs, boost ASC payment rate 2.6% in 2020: 4 details
With $60B+ deals this year, what’s in store for private equity in the future?
Texas health system building ASC — 4 insights
